Medicare Part D beneficiaries who received retail and specialty drugs from prescribers at 340B disproportionate share hospitals (DSH) were more [...] …
Articles by : Shannon Young, Associate Editor/Senior Writer
Ohio is the latest state to consider proposed legislation that would ban drugmakers from restricting covered entities’ acquisition of 340B [...] …
A Kansas law that prohibits drugmaker 340B contract pharmacy restrictions is set to take effect July 1, as result of [...] …
The 340B program continued to expand in 2023, exceeding $124 billion in wholesale acquisition cost (WAC) sales—up from $107 billion [...] …
North Carolina hospitals that participate in the 340B program routinely overcharged cancer patients, taxpayers and state employees for oncology drugs, [...] …
Groups representing hospitals that rely on the 340B program recently urged congressional advisers against recommending reduced Medicare reimbursement to 340B [...] …
While newly enrolled 340B hospital entrants served higher numbers of Medicaid and rural patients than non-340B hospitals, government-owned 340B hospitals [...] …
Drugmaker Novo Nordisk this week announced that its contract pharmacy restrictions will soon apply to all grantee covered entities—not just [...] …
As 340B stakeholders continue to hold out for long-awaited congressional action that could overhaul the discount drug pricing program, some [...] …
Just weeks after passing legislation to prohibit drugmaker 340B contract pharmacy restrictions in the state, Kansas lawmakers voted late Tuesday [...] …